세계의 유전자 치료 플랫폼 시장 규모, 점유율, 동향 분석 보고서 : 플랫폼 유형별, 치료 용도별, 전달 모드별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

Gene Therapy Platform Market Size, Share & Trends Analysis Report By Platform Type (Viral Vector Platforms, Non-Viral Vector Platforms), By Therapeutic Application, By Delivery Mode, By End Use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세게의 유전자 치료 플랫폼 시장 규모와 동향

세계의 유전자 치료 플랫폼 시장 규모는 2024년에 21억 4,000만 달러로 추정되고, 2025-2030년까지 CAGR 15.2%를 보일 것으로 예측됩니다.

이러한 성장은 급속한 기술 진보, 유전성 질환 및 만성 질환의 유병률 증가, 바이오 의약품 연구에 대한 투자 및 자금 조달 확대, 신속한 승인을 촉진하는 지지적 규제 프레임워크 등 몇 가지 주요 촉진요인에 의해 야기됩니다.

바이러스 벡터 기술, CRISPR을 포함한 유전자 편집 툴, AI 통합, 제조에 있어서의 자동화 등의 기술 혁신은 치료의 정확성과 생산 효율을 높이고 있습니다.

희귀질환과 유전성 질환을 대상으로 하는 유전자 치료의 FDA 승인 건수 증가는 이러한 플랫폼의 임상적 가능성을 검증하고 투자와 연구 개발을 촉진하고 있습니다. 2023년 12월, Exagamglogene autotemcel(Casgevy)와 같은 CRISPR 기반 치료법은 겸상 적혈구증과 베타-살라세미아에 대한 FDA의 승인을 받았으며, 유전자 요법에서 중요한 이정표가 되었습니다.

유전성 질환과 만성 질환의 유병률이 세계적으로 상승하고 있는 것이 분자 수준에서 질환을 표적으로 하는 유전자 치료에 대한 수요를 부추기고 있습니다. WHO는 2024년, 세계적으로 암 환자가 급증할 것으로 예측하고 있으며, 2050년까지 새롭게 발생하는 암 환자는 3,500만명을 넘을 것으로 예상되고 있습니다. 이러한 환자수 증가는 선진적 치료에 대한 긴급 수요를 낳아, 미충족 의료 요구에 대응하기 위한 유전자 치료 기술에 대한 투자와 기술 혁신을 촉진합니다.

게다가 혁신적인 치료법에 대한 규제 당국의 지원이 시장 성장을 뒷받침하고 있습니다. 희귀 의약품(오판 드래그) 스테이터스 등의 규제상의 우대조치가 유전자 치료의 개발을 더욱 뒷받침하고 있습니다.

COVID-19의 대유행은 시장에 큰 영향을 미치고 임상 검사, 제조, 공급망을 혼란시켰습니다. 이런 과제에도 불구하고 팬데믹은 기술 혁신에도 박차를 가하고 일부 유전자 치료 개발 기업은 COVID-19 관련 치료나 백신에 임해 유전자 치료 부문의 회복력과 가능성을 부각시켰습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 유전자 치료 플랫폼 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
  • 산업의 과제와 기회의 분석
• 유전자 치료 플랫폼 시장 분석 툴
  • Porter's Five Forces 분석
  • PESTEL 분석
• 규제 프레임워크
• 신흥기술
• COVID-19에 의한 유전자 치료 플랫폼 시장에 대한 영향
• 이용 사례와 통찰

제4장 유전자 치료 플랫폼 시장 : 플랫폼 유형별, 추정 및 동향 분석

• 정의와 범위
• 플랫폼 유형 시장 점유율 분석, 2024년 및 2030년
• 부문 대시보드
• 유전자 치료 플랫폼 시장 : 플랫폼 유형별, 2018-2030년
• 바이러스 벡터 플랫폼
  • 아데노 관련 바이러스(AAV)
  • 렌티바이러스
  • 레트로바이러스
  • 아데노바이러스
  • 단순 헤르페스 바이러스(HSV)
• 비바이러스 벡터 플랫폼
  • 지질 나노입자(LNP)
  • 일렉트로포레이션 및 마이크로 인젝션 플랫폼
  • 폴리머 기반 전달 시스템
  • 알몸의 DNA/RNA 전달
• 유전자 편집 플랫폼
  • CRISPR-Cas 시스템
  • TALENs
  • ZFN

제5장 유전자 치료 플랫폼 시장 : 치료 용도별, 추정 및 동향 분석

• 정의와 범위
• 치료용도 시장 점유율 분석, 2024년 및 2030년
• 부문 대시보드
• 유전자 치료 플랫폼 시장 : 치료 용도별, 2018-2030년
• 종양학
• 희귀 유전성 질환
• 심혈관 질환
• 신경질환
• 안과 질환
• 혈액 질환(예:혈우병, 겸상 적혈구증)
• 근골격계 장애
• 감염증(예: HIV, COVID-19의 보조요법)

제6장 유전자 치료 플랫폼 시장 : 전달 모드별, 추정 및 동향 분석

• 정의와 범위
• 전달 모드 시장 점유율 분석, 2024년 및 2030년
• 부문 대시보드
• 유전자 치료 플랫폼 시장 : 전달 모드별, 2018-2030년
• 생체내 유전자 치료
• 체외 유전자 치료
  • 자가 세포를 이용한 유전자 치료
  • 동종 세포를 이용한 유전자 치료
• 기타(원위치 유전자 치료)

제7장 유전자 치료 플랫폼 시장 : 최종 용도별, 추정 및 동향 분석

• 정의와 범위
• 최종 용도 시장 점유율 분석, 2024년 및 2030년
• 부문 대시보드
• 유전자 치료 플랫폼 시장 : 최종 용도별, 2018-2030년
• 제약 및 바이오테크놀러지 기업
• 학술연구기관
• 계약 개발 제조 조직(CDMO)
• 병원 및 유전자 치료 센터

제8장 유전자 치료 플랫폼 시장 : 플랫폼 유형, 치료 용도, 전달 방법, 최종 용도에 따른 지역별, 추정 및 동향 분석

• 정의와 범위
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 시장 대시보드
• 지역 시장 현황
• SWOT 분석
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 유전자 치료 플랫폼 시장 점유율(지역별, 2024년 및 2030년, 100만 달러)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 덴마크
  • 노르웨이
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 기업의 시장 점유율 분석
• 기업 히트맵 분석
• 기업 프로파일
  • Lonza
  • BioIT
  • Autolomous Ltd
  • Hypertrust Patient Data Care(Accenture 산하)
  • IBM
  • L7 Informatics, Inc.
  • TrakCel
  • IDBS
  • Novartis
  • SAP SE
  • DEEP GENOMICS
  • ElevateBio
  • Sarepta Therapeutics, Inc.
  • CRISPR Therapeutics
  • Precision BioSciences
  • AstraZeneca
  • Andelyn Biosciences
  • Renova Therapeutics

>JHS

영문 목차

영문목차

Gene Therapy Platform Market Size & Trends:

The global gene therapy platform market size was estimated at USD 2.14 billion in 2024 and is projected to grow at a CAGR of 15.2% from 2025 to 2030. The growth is driven by several key drivers, including rapid technological advancements, increasing prevalence of genetic and chronic diseases, growing investments and funding in biopharmaceutical research, and supportive regulatory frameworks facilitating faster approvals.

Innovations in viral vector technologies, gene editing tools including CRISPR, integration of AI and automation in manufacturing are enhancing therapy precision and production efficiency. For instance, in March 2023, Catalent is enhancing its UpTempo AAV platform to speed up the development of gene therapies.

The increasing number of FDA approvals for gene therapies targeting rare and genetic diseases has validated the clinical potential of these platforms, encouraging investment and R&D. For instance, in December 2023[, CRISPR-based therapies, like Exagamglogene autotemcel (Casgevy), received FDA approval for sickle cell disease and beta-thalassemia, marking a significant milestone in gene therapy. These breakthroughs are pushing the field forward, enabling more efficient technology for various genetic disorders.

The rising prevalence of genetic disorders and chronic diseases worldwide, is fueling demand for gene therapies that target disease at the molecular level. Conditions such as cystic fibrosis, hemophilia, spinal muscular atrophy, and various cancers are increasingly treated with gene therapy approaches that offer potentially curative outcomes. The World Health Organization (WHO) in 2024 projected a sharp increase in cancer cases globally, with over 35 million new cases expected by 2050, up 77% from 2022. This growing patient pool creates urgent demand for advanced treatments, driving investment and innovation in gene therapy technologies to address unmet medical needs.

Moreover, regulatory support for innovative therapies is driving market growth. Regulatory agencies, including the FDA and the European Medicines Agency (EMA), have streamlined approval processes for gene therapies, recognizing their transformative potential. In addition, regulatory incentives such as fast-track designations and orphan drug status further support the development of gene therapies. These measures help reduce development timelines and encourage the introduction of new treatments to address unmet medical needs.

The COVID-19 pandemic significantly impacted the market, disrupting clinical trials, manufacturing, and supply chains. The increased demand for raw materials for COVID-19 vaccine production caused shortages, affecting the availability of essential components for gene therapy manufacturing. Despite these challenges, the pandemic also spurred innovation, with some gene therapy developers adapting their efforts toward COVID-19-related therapeutics and vaccines, highlighting the resilience and potential of the gene therapy sector.

Global Gene Therapy Platform Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global gene therapy platform market report based on platform type, application, delivery method, end use, and region.

• Platform Type Outlook (Revenue, USD Million, 2018 - 2030)
• Viral Vector Platforms
  • Adeno-associated Virus (AAV)
  • Lentivirus
  • Retrovirus
  • Adenovirus
  • Herpes Simplex Virus (HSV)
• Non-Viral Vector Platforms
  • Lipid Nanoparticles (LNPs)
  • Electroporation & Microinjection Platforms
  • Polymer-based Delivery Systems
  • Naked DNA/RNA Delivery
• Gene Editing Platforms
  • CRISPR-Cas Systems
  • TALENs
  • ZFNs
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Oncology
• Rare Genetic Disorders
• Cardiovascular Diseases
• Neurological Disorders
• Ophthalmic Diseases
• Hematological Disorders (e.g., Hemophilia, Sickle Cell)
• Musculoskeletal Disorders
• Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
• Delivery Mode Outlook (Revenue, USD Million, 2018 - 2030)
• In Vivo Gene Therapy
• Ex Vivo Gene Therapy
  • Autologous Cell-Based Gene Therapy
  • Allogeneic Cell-Based Gene Therapy
• Others (In-situ Gene therapy)
• End Use Outlook (Revenue, USD Million, 2018 - 2030)
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• Contract Development & Manufacturing Organizations (CDMOs)
• Hospitals & Gene Therapy Centers
• Regional Outlook (Revenue, USD Million, 2018-2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Scope
  • 1.2.1. Platform Type
  • 1.2.2. Application
  • 1.2.3. Delivery Method
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Platform Type Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Delivery Method Outlook
  • 2.2.4. End Use Outlook
  • 2.2.5. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Gene Therapy Platform Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising prevalence of genetic disorders
    • 3.2.1.2. Advancements in gene editing technologies
    • 3.2.1.3. Supportive regulatory frameworks
    • 3.2.1.4. Growing investment and strategic partnerships
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of development and treatment
  • 3.2.3. Industry Challenges and Opportunity Analysis
• 3.3. Gene Therapy Platform Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological Landscape
    • 3.3.2.4. Environmental Landscape
    • 3.3.2.5. Legal Landscape
• 3.4. Regulatory Framework
• 3.5. Emerging Technologies
• 3.6. Impact of COVID 19 on the Gene Therapy Platform Market
• 3.7. Case Study & Insights

Chapter 4. Gene Therapy Platform Market: Platform Type Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Platform Type Market Share Analysis, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Gene Therapy Platform Market: By Platform Type, 2018 to 2030
• 4.5. Viral Vector Platforms
  • 4.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Adeno-associated Virus (AAV)
    • 4.5.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Lentivirus
    • 4.5.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Retrovirus
    • 4.5.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.5. Adenovirus
    • 4.5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.6. Herpes Simplex Virus (HSV)
    • 4.5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Non-Viral Vector Platforms
  • 4.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.2. Lipid Nanoparticles (LNPs)
    • 4.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.3. Electroporation & Microinjection Platforms
    • 4.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.4. Polymer-based Delivery Systems
    • 4.6.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6.5. Naked DNA/RNA Delivery
    • 4.6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Gene Editing Platforms
  • 4.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.2. CRISPR-Cas Systems
    • 4.7.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.3. TALENs
    • 4.7.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7.4. ZFNs
    • 4.7.4.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Gene Therapy Platform Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Gene Therapy Platform Market: By Application, 2018 to 2030
• 5.5. Oncology
  • 5.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Rare Genetic Disorders
  • 5.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Cardiovascular Diseases
  • 5.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Neurological Disorders
  • 5.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Ophthalmic Diseases
  • 5.9.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.10. Hematological Disorders (e.g., Hemophilia, Sickle Cell)
  • 5.10.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.11. Musculoskeletal Disorders
  • 5.11.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.12. Infectious Diseases (e.g., HIV, COVID-19 adjunct therapies)
  • 5.12.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Gene Therapy Platform Market: Delivery Method Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. Delivery Mode Market Share Analysis, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Gene Therapy Platform Market: By Delivery Mode, 2018 to 2030
• 6.5. In Vivo Gene Therapy
  • 6.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Ex Vivo Gene Therapy
  • 6.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.2. Autologous Cell-Based Gene Therapy
    • 6.6.2.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Allogeneic Cell-Based Gene Therapy
    • 6.6.3.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others (In-situ Gene therapy)
  • 6.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Gene Therapy Platform Market: End Use Estimates & Trend Analysis

• 7.1. Definition and Scope
• 7.2. End Use Market Share Analysis, 2024 & 2030
• 7.3. Segment Dashboard
• 7.4. Gene Therapy Platform Market: By End Use, 2018 to 2030
• 7.5. Pharmaceutical & Biotechnology Companies
  • 7.5.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Academic & Research Institutions
  • 7.6.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Contract Development & Manufacturing Organizations (CDMOs)
  • 7.7.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Hospitals & Gene Therapy Centers
  • 7.8.1. Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Gene Therapy Platform Market: Regional Estimates & Trend Analysis by Platform Type, Therapeutic Application, Delivery Method, and End Use

• 8.1. Definition and Scope
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Regional Market Dashboard
• 8.4. Regional Market Snapshot
• 8.5. SWOT Analysis
  • 8.5.1. North America
  • 8.5.2. Europe
  • 8.5.3. Asia Pacific
  • 8.5.4. Latin America
  • 8.5.5. Middle East & Africa
• 8.6. Gene Therapy Platform Market Share, By Region, 2024 & 2030, USD Million
• 8.7. North America
  • 8.7.1. North America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. U.S.
    • 8.7.2.1. U.S. Key Country Dynamics
    • 8.7.2.2. Regulatory Landscape
    • 8.7.2.3. Competitive Insights
    • 8.7.2.4. U.S. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Canada
    • 8.7.3.1. Canada Key Country Dynamics
    • 8.7.3.2. Regulatory Landscape
    • 8.7.3.3. Competitive Insights
    • 8.7.3.4. Canada Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.4. Mexico
    • 8.7.4.1. Mexico Key Country Dynamics
    • 8.7.4.2. Regulatory Landscape
    • 8.7.4.3. Competitive Insights
    • 8.7.4.4. Mexico Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Europe
  • 8.8.1. Europe Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. UK
    • 8.8.2.1. UK Key Country Dynamics
    • 8.8.2.2. Regulatory Landscape
    • 8.8.2.3. Competitive Insights
    • 8.8.2.4. U.K. Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Germany
    • 8.8.3.1. Germany Key Country Dynamics
    • 8.8.3.2. Regulatory Landscape
    • 8.8.3.3. Competitive Insights
    • 8.8.3.4. Germany Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. France
    • 8.8.4.1. France Key Country Dynamics
    • 8.8.4.2. Regulatory Landscape
    • 8.8.4.3. Competitive Insights
    • 8.8.4.4. France Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Italy
    • 8.8.5.1. Italy Key Country Dynamics
    • 8.8.5.2. Regulatory Landscape
    • 8.8.5.3. Competitive Insights
    • 8.8.5.4. Italy Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.6. Spain
    • 8.8.6.1. Spain Key Country Dynamics
    • 8.8.6.2. Regulatory Landscape
    • 8.8.6.3. Competitive Insights
    • 8.8.6.4. Spain Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.7. Sweden
    • 8.8.7.1. Sweden Key Country Dynamics
    • 8.8.7.2. Regulatory Landscape
    • 8.8.7.3. Competitive Insights
    • 8.8.7.4. Sweden Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.8. Denmark
    • 8.8.8.1. Denmark Key Country Dynamics
    • 8.8.8.2. Regulatory Landscape
    • 8.8.8.3. Competitive Insights
    • 8.8.8.4. Denmark Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.9. Norway
    • 8.8.9.1. Norway Key Country Dynamics
    • 8.8.9.2. Regulatory Landscape
    • 8.8.9.3. Competitive Insights
    • 8.8.9.4. Norway Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.9. Asia Pacific
  • 8.9.1. Asia Pacific Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.2. China
    • 8.9.2.1. China Key Country Dynamics
    • 8.9.2.2. Regulatory Landscape
    • 8.9.2.3. Competitive Insights
    • 8.9.2.4. China Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.3. Japan
    • 8.9.3.1. Japan Key Country Dynamics
    • 8.9.3.2. Regulatory Landscape
    • 8.9.3.3. Competitive Insights
    • 8.9.3.4. Japan Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.4. India
    • 8.9.4.1. India Key Country Dynamics
    • 8.9.4.2. Regulatory Landscape
    • 8.9.4.3. Competitive Insights
    • 8.9.4.4. India Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.5. South Korea
    • 8.9.5.1. South Korea Key Country Dynamics
    • 8.9.5.2. Regulatory Landscape
    • 8.9.5.3. Competitive Insights
    • 8.9.5.4. South Korea Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.6. Australia
    • 8.9.6.1. Australia Key Country Dynamics
    • 8.9.6.2. Regulatory Landscape
    • 8.9.6.3. Competitive Insights
    • 8.9.6.4. Australia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.9.7. Thailand
    • 8.9.7.1. Thailand Key Country Dynamics
    • 8.9.7.2. Regulatory Landscape
    • 8.9.7.3. Competitive Insights
    • 8.9.7.4. Thailand Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.10. Latin America
  • 8.10.1. Latin America Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.10.2. Brazil
    • 8.10.2.1. Brazil Key Country Dynamics
    • 8.10.2.2. Regulatory Landscape
    • 8.10.2.3. Competitive Insights
    • 8.10.2.4. Brazil Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.10.3. Argentina
    • 8.10.3.1. Argentina Key Country Dynamics
    • 8.10.3.2. Regulatory Landscape
    • 8.10.3.3. Competitive Insights
    • 8.10.3.4. Argentina Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.11. Middle East and Africa
  • 8.11.1. Middle East and Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.2. South Africa
    • 8.11.2.1. South Africa Key Country Dynamics
    • 8.11.2.2. Regulatory Landscape
    • 8.11.2.3. Competitive Insights
    • 8.11.2.4. South Africa Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.3. Saudi Arabia
    • 8.11.3.1. Saudi Arabia Key Country Dynamics
    • 8.11.3.2. Regulatory Landscape
    • 8.11.3.3. Competitive Insights
    • 8.11.3.4. Saudi Arabia Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.4. UAE
    • 8.11.4.1. UAE Key Country Dynamics
    • 8.11.4.2. Regulatory Landscape
    • 8.11.4.3. Competitive Insights
    • 8.11.4.4. UAE Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.11.5. Kuwait
    • 8.11.5.1. Kuwait Key Country Dynamics
    • 8.11.5.2. Regulatory Landscape
    • 8.11.5.3. Competitive Insights
    • 8.11.5.4. Kuwait Gene Therapy Platform Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share Analysis
• 9.3. Company Heat Map Analysis
• 9.4. Company Profiles
  • 9.4.1. Lonza
    • 9.4.1.1. Participant's Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Recent Developments
  • 9.4.2. BioIT
    • 9.4.2.1. Participant's Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Recent Developments
  • 9.4.3. Autolomous Ltd
    • 9.4.3.1. Participant's Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Recent Developments
  • 9.4.4. Hypertrust Patient Data Care (Part of Accenture)
    • 9.4.4.1. Participant's Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Recent Developments
  • 9.4.5. IBM
    • 9.4.5.1. Participant's Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Recent Developments
  • 9.4.6. L7 Informatics, Inc.
    • 9.4.6.1. Participant's Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Recent Developments
  • 9.4.7. TrakCel
    • 9.4.7.1. Participant's Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Recent Developments
  • 9.4.8. IDBS
    • 9.4.8.1. Participant's Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Recent Developments
  • 9.4.9. Novartis
    • 9.4.9.1. Participant's Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Recent Developments
  • 9.4.10. SAP SE
    • 9.4.10.1. Participant's Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Recent Developments
  • 9.4.11. DEEP GENOMICS
    • 9.4.11.1. Participant's Overview
    • 9.4.11.2. Financial Performance
    • 9.4.11.3. Product Benchmarking
    • 9.4.11.4. Recent Developments
  • 9.4.12. ElevateBio
    • 9.4.12.1. Participant's Overview
    • 9.4.12.2. Financial Performance
    • 9.4.12.3. Product Benchmarking
    • 9.4.12.4. Recent Developments
  • 9.4.13. Sarepta Therapeutics, Inc.
    • 9.4.13.1. Participant's Overview
    • 9.4.13.2. Financial Performance
    • 9.4.13.3. Product Benchmarking
    • 9.4.13.4. Recent Developments
  • 9.4.14. CRISPR Therapeutics
    • 9.4.14.1. Participant's Overview
    • 9.4.14.2. Financial Performance
    • 9.4.14.3. Product Benchmarking
    • 9.4.14.4. Recent Developments
  • 9.4.15. Precision BioSciences
    • 9.4.15.1. Participant's Overview
    • 9.4.15.2. Financial Performance
    • 9.4.15.3. Product Benchmarking
    • 9.4.15.4. Recent Developments
  • 9.4.16. AstraZeneca
    • 9.4.16.1. Participant's Overview
    • 9.4.16.2. Financial Performance
    • 9.4.16.3. Product Benchmarking
    • 9.4.16.4. Recent Developments
  • 9.4.17. Andelyn Biosciences
    • 9.4.17.1. Participant's Overview
    • 9.4.17.2. Financial Performance
    • 9.4.17.3. Product Benchmarking
    • 9.4.17.4. Recent Developments
  • 9.4.18. Renova Therapeutics
    • 9.4.18.1. Participant's Overview
    • 9.4.18.2. Financial Performance
    • 9.4.18.3. Product Benchmarking
    • 9.4.18.4. Recent Developments

관련자료